Denali Therapeutics/DNLI

$18.04

-4.55%
-
1D1W1MYTD1YMAX

About Denali Therapeutics

Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates. Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). SAR443820/DNL788 (RIPK1 inhibitor) is being evaluated in a Phase II study for multiple sclerosis (MS). In addition, it has a Phase I/II study of TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN) and a Phase I/II study of DNL126 for MPS IIIA (Sanfilippo syndrome).

Ticker

DNLI

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Ryan Watts

Employees

375

Headquarters

South san francisco, United States

DNLI Metrics

BasicAdvanced
$2.7B
Market cap
-
P/E ratio
-$0.97
EPS
1.37
Beta
-
Dividend rate
$2.7B
1.36951
$33.31
$14.56
1.2M
11.789
-9.18%
-11.33%
-10.91%
9.274
1.881
1.882
191.13%
66.23%
-0.51%

What the Analysts think about DNLI

Analyst Ratings

Majority rating from 17 analysts.
Buy

Price Targets

Average projection from 16 analysts.
120.01% upside
High $95.00
Low $22.00
$18.04
Current price
$39.69
Average price target

DNLI Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$102M
-14.74%
Profit margin
0%
NaN%

DNLI Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 3.25%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$1.30
-$0.72
-$0.86
-$0.68
-
Expected
-$0.68
-$0.80
-$0.80
-$0.70
-$0.67
Surprise
-290.08%
-10.28%
6.94%
-3.25%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Denali Therapeutics stock?

Denali Therapeutics (DNLI) has a market cap of $2.7B as of May 29, 2024.

What is the P/E ratio for Denali Therapeutics stock?

The price to earnings (P/E) ratio for Denali Therapeutics (DNLI) stock is 0 as of May 29, 2024.

Does Denali Therapeutics stock pay dividends?

No, Denali Therapeutics (DNLI) stock does not pay dividends to its shareholders as of May 29, 2024.

When is the next Denali Therapeutics dividend payment date?

Denali Therapeutics (DNLI) stock does not pay dividends to its shareholders.

What is the beta indicator for Denali Therapeutics?

Denali Therapeutics (DNLI) has a beta rating of 1.37. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Denali Therapeutics stock price target?

The target price for Denali Therapeutics (DNLI) stock is $39.69, which is 120.01% above the current price of $18.04. This is an average based on projections from 16 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Denali Therapeutics stock

Buy or sell Denali Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing